文献速递心外重症与机械循环支持

静脉-肺动脉体外生命支持:ELSO登记研究分析

Venopulmonary extracorporeal life support: An Extracorporeal Life Support Organization registry analysis.
PubMed 文献 · J Heart Lung Transplant · 2026-01-06

该研究基于ELSO登记数据库,纳入2020年7月至2024年7月接受VP ECLS作为首选支持的838例成人患者,按诊断分组分析不良事件与预后。结果显示VP ECLS主要用于心衰/心源性休克(54.4%)和急性呼吸衰竭/ARDS(26.6%),60天生存率49.3%,年龄、女性、BMI及插管前CRRT使用为死亡独立预测因素。

要点

  • VP ECLS主要用于心衰/心源性休克和急性呼吸衰竭/ARDS。
  • 60天生存率49.3%,非幸存者并发症更常见且模式因诊断而异。
  • 年龄增长、女性、较高BMI及插管前CRRT使用增加死亡风险。

核心结论

  • VP ECLS主要用于心衰/心源性休克和急性呼吸衰竭/ARDS,不同诊断的结局与并发症模式存在差异。
  • 年轻、男性、较低BMI及插管前未使用CRRT与较低死亡风险相关。

研究设计与样本

  • 回顾性登记研究,查询ELSO登记数据库,纳入2020年7月至2024年7月接受VP ECLS作为首选支持模式的全部成人患者,共838例。

主要发现

  • 838例患者中女性占32.3%,年龄8(46, 67)岁。
  • 心衰/心源性休克占54.4%,急性呼吸衰竭/ARDS占26.6%,心脏术后休克占6.7%,急性冠脉综合征/缺血性心脏病占5.3%,瓣膜性心脏病/心内装置并发症占4.2%,肺栓塞占2.9%。
  • 最常见不良事件包括CRRT使用或急性肾损伤(37.4%)、感染(35.4%)、心律失常(13.5%)、手术部位出血(12.1%)、胃肠道出血(6.1%)。
  • Kaplan-Meier估计60天生存率为49.3(45.3, 53.1)%。
  • 死亡独立预测因素包括年龄(每增加5岁HRadj 1.15;95%CI 1.11, 1.20;p < 0.001)、女性(HRadj 1.40;95%CI 1.12, 1.76;p = 0.003)、BMI(每增加3 kg/m2 HRadj 1.02;95%CI 1.01, 1.04;p < 0.018)、VP ECLS插管前CRRT使用(HRadj 1.44;95%CI 1.11, 1.86;p < 0.006)。

临床怎么用

  • VP ECLS决策时应考虑诊断类别对并发症模式和生存的影响。
  • 对高龄、女性、较高BMI及插管前需CRRT的患者应加强风险评估。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is a paucity of data informing on the current use, adverse events, outcomes, and prognostic drivers for patients receiving venopulmonary extracorporeal life support (VP ECLS). We aimed to provide a contemporary, large sample size study to describe the real-world outcomes of adults supported with VP ECLS across different clinical conditions. METHODS: We queried the Extracorporeal Life Support Organization Registry to retrieve all adult patients who received VP ECLS as the first support modality from July 2020 to July 2024. Study population was grouped according to hospital death outcome and to the diagnosis leading to VP ECLS use. Adverse outcomes are reported according to the diagnosis leading to VP ECLS use. A time-to-event Cox regression model was applied to identify predictors of death. RESULTS: A total of 838 patients [32.3% females; age 8 (46, 67) years] were included. Patients were treated for heart failure/cardiogenic shock (HF/CS) in 54.4%, for acute respiratory failure/acute respiratory distress syndrome (ARF/ARDS) in 26.6%, for post-cardiotomy shock in 6.7%, for acute coronary syndrome/ischemic heart disease in 5.3%, for valvular heart disease/complications of intracardiac devices in 4.2%, and for pulmonary embolism in 2.9%. Most common adverse events included continuous renal replacement therapy (CRRT) use or acute kidney injury (37.4%), infections (35.4%), cardiac arrhythmias (13.5%), surgical site bleeding (12.1%), gastrointestinal (GI) bleeding (6.1%). Complications were more common in non-survivors and patterns of complications differed among diagnosis groups. The Kaplan-Meier estimated 60-day survival was 49.3 (45.3, 53.1)%. Age (HRadj 1.15 for 5 years increase; 95%CI 1.11, 1.20; p < 0.001), female sex (HRadj 1.40; 95%CI 1.12, 1.76; p = 0.003), body mass index (HRadj 1.02 for 3 kg/m2 increase; 95%CI 1.01, 1.04; p < 0.018), CRRT use prior VP ECLS cannulation (HRadj 1.44; 95%CI 1.11, 1.86; p < 0.006) were independent predictors of death. CONCLUSIONS: In this large Extracorporeal Life Support Organization registry analysis, VP ECLS was chiefly used for HF/CS and ARF/ARDS. Hospital outcomes, complications, and survival differed according to the diagnosis leading to VP ECLS use. Younger age, male sex, lower BMI, and no CRRT use prior to VP ECLS cannulation confer a lower risk of death and provide targets for future research and potential domains for clinical improvement.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Baldetti L, Pontillo D, Capoccia M, et al. Venopulmonary extracorporeal life support: An Extracorporeal Life Support Organization registry analysis. J Heart Lung Transplant. 2026. PMID: 41506589. doi:10.1016/j.healun.2025.12.024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。